INTRODUCTION
============

Dental caries caused by *Streptococcus mutans* is a global oral health problem. Glucosyltransferases of the cariogenic streptococci synthesize insoluble glucan-biofilm on the tooth surfaces, and the glucan contributes to the formation of tartar and plaque \[[@R1]\]. The insoluble glucan on tooth surfaces mediates bacterial colonization and is an essential element in the pathogenesis of dental caries \[[@R2]\]. Therefore, a key for the prevention of dental caries is bactericidal ability against *S. mutans* \[[@R3]\]. Furthermore, inhibition of insoluble glucan synthesis is required to maintain oral health.

Nisin is an antimicrobial peptide, produced by *Lactococcus lactis* subsp. *lactis*. This class IA lantibiotic has the ability to inhibit Gram-positive bacteria \[[@R4]\]. Nisin has been identified to suppress *S. mutans in vitro* \[[@R5]\]. Nisin does not appear to be toxic to normal human gingival fibroblasts and epithelial cells \[[@R6]\]. However, nisin is negatively affected by proteolytic degradation, oxidation, and its own insolubility *in vitro* and *in vivo*. Liposomes are accepted to encapsulate several bioactive molecules, and these molecules are entrapped in the lipid layer or in the aqueous core depending on the molecule's inherent lipophilicity or hydrophilicity \[[@R7]\]. Thus, liposomes have been demonstrated to be effective for encapsulating unstable bioactive molecules, and also safe for human consumption. Lipid selection is based on the vesicle stabilizing capacity, and the vesicles can express the complete biological ability of the encapsulated molecules. Liposomes have gained attention as biocompatible carriers, and the expected function is their ability to protect the entrapped molecules within the lipid vesicles \[[@R8]\]. The applications of liposome encapsulation of antimicrobial peptides have been developed for food chemistry \[[@R5]\]. Stabilized liposomes with a prolonged lifetime of encapsulated nisin have been investigated for maximal efficiency. For preventing dental caries, liposome-encapsulated nisin is an attractive approach \[[@R9]\]. We are exploiting the physical stability profile of liposome-encapsulated nisin *in vitro* and have observed that liposome-encapsulated nisin shows bactericidal activity against *S. mutans* but there are few data describing the ability of liposome-encapsulated nisin for preventing dental caries \[[@R10]\]. In recent studies, the effects of acyl chain length of phosphatidylcholine on nisin activity have been shown to influence the effectiveness of bactericidal activity against *S. mutans* and the inhibitory effect on insoluble glucan synthesis \[[@R11]\]. However, the outcome of our effort to effectively facilitate sustained nisin activity has not yet been encouraging. Efficiency of charged lipid on the liposome-encapsulated nisin has not been investigated with the intent of prevention for dental caries. The aim of our study was to design a candidate lipid formulation for long lasting bactericidal activity by the sustained release of nisin from the liposomes. Here we evaluated the liposome compositions formulated with charged lipids for optimizing their ability of bactericidal activity against *S. mutans* and their influences on the inhibition of insoluble glucan formation.

MATERIALS AND METHODS
=====================

Preparation of Nisin
--------------------

Nisin was obtained from *Lactococcus lactis* subsp. *lactis* 11454 (American Type Culture Collection; Manassas, VA, USA) and was purified, as described previously \[[@R4], [@R10]\]. Briefly, pellets of cultured *L. lactis* were suspended in 70% isopropanol/0.1% trifluoroacetic acid. The suspension was centrifuged at 7,000×*g* for 10 min, and the supernatant fluid was evaporated. The clarified materials were subsequently subjected to reverse-phase HPLC using a C-8 column (YMC Inc., Kyoto, Japan) pre-equilibrated with 0.1% trifluoroacetic acid, and the resulting profile was monitored at 220 nm. For elution of nisin, the column was developed in a linear gradient 70% isopropanol/0.1% trifluoroacetic acid. To determine the purity of nisin, peak fractions were re-run on the C-8 column, and the purity was assessed using chromatography at 220 nm. Nisin of \>95% purity was used in this study. The purified fractions were passed through a membrane filter with 0.22 µm pore size. The solutions of 0.3 µmol each of the purified nisin were placed into vial and then lyophilized. The vials were stored at 4°C until use.

Preparation of Liposome-encapsulated Nisin
------------------------------------------

We used the following lipids: dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylethanolamine (DPPE) and stearoylphytosphingosine (SPS) as the electroneutral lipid; dipalmitoylphosphatidylglycerol (DPPG) as the anionic lipid; and phytosphingosine (PS) as the cationic lipid (Avanti Polar Lipids. Inc., Alabaster, AL, USA). Two lipid molar formations: DPPC/DPPG, DPPC/DPPE, DPPC/SPS, and DPPC/PS (85:15 mol%) were prepared for liposomes. DPPC (100%) was placed as the control liposome. The liposomes were prepared using the freeze-dried empty liposomes (FDEL) method \[[@R12]\]. Briefly, appropriate amounts of the each composition of lipids were dissolved in chloroform, and the solvent was removed by evaporation. These lipids were evacuated and then hydrated with water at 60°C. The dispersions were passed through a membrane filter with a 0.22 µm pore size. The dispersions of 40 µmol as the lipids were placed in vial, and then lyophilized. The vials were stored at 4°C until use. To prepare liposome-encapsulated nisin, the lyophilized nisin in a vial was dissolved with 1 ml of 5 mM sodium citrate (pH 5.0). The materials were transferred to the vial of FDEL (40 µmol) and then vortexed, thus obtaining the compositions of 0.3 µmol nisin/40 µmol lipids as the liposome-encapsulated nisin. To determine the efficiency of encapsulation of nisin, 20 µl of liposomes were mixed with 80 µl of an aqueous solution of 2% Triton X-100 and incubated at 37°C to release nisin. Encapsulation efficiency was determined by comparing the amounts of starting and released nisin using a CBQCA protein assay kit (Molecular Probes, Eugene, OR, USA) according to the manufacturer's instructions.

Assay of Bactericidal Activity of Liposome-encapsulated Nisin
-------------------------------------------------------------

Determinations of the minimum inhibitory concentrations (MIC) as indicative of the bactericidal activity of liposome preparations against *S*. *mutans* 10449 (American Type Culture Collection) were performed using the broth dilution method \[[@R13]\]. Amounts of *S. mutans* were measured the turbidity at 600 nm \[[@R10]\]. The liposome preparations were added to 96 well flat-bottom microplates at final concentrations of 5-250 pmol in 50 µl of 10 mM sodium citrate (pH 7.0). *S*. *mutans* 10449 in 50 µl of Todd Hewitt Broth (THB; Invitrogen, Carlsbad, CA, USA) containing resazurin dye (Sigma-Aldrich, St. Louis, MO, USA) were added to the wells; the plates were incubated at 37°C for 4 h and then assayed colorimetrically at 570 nm \[[@R14]\]. The MIC values were defined as the lowest amounts of nisin that inhibited the growth of *S*. *mutans*.

Assay of the Inhibitory Effect of Liposome-encapsulated Nisin on Insoluble Glucan Synthesis
-------------------------------------------------------------------------------------------

The effects of nisin-loaded liposome on the synthesis of insoluble glucan were assayed by the method of our previous report \[[@R10]\]. Insoluble glucan was generated using *S*. *mutans* cultured in 96 well flat-bottom microplates. Assays were performed using a solution containing *S*. *mutans* in 50 µl of THB, 50 µl of 1.0% sucrose, and bacteriocin (naked nisin, 75 pmol; and nisin-loaded liposome, 75 pmol as the nisin equivalent) in 100 µl of 5 mM sodium citrate (pH 7.0) were added to individual wells. The plates were incubated at 37°C, and insoluble glucans were quantified at appropriate time points. Insoluble glucans in each well were washed with 10 mM sodium phosphate buffer (pH 7.0) and dissolved with 200 µl of 1.0 M sodium hydroxide. The amounts of alkaline solubilized glucan were quantified by the phenol-sulfuric acid method \[[@R15]\]. Inhibition of glucan synthesis was determined according to the amounts of insoluble glucan in each well compared with those in wells lacking nisin or liposomes.

*In Vitro* Nisin Release Assay from Liposome-encapsulated Nisin
---------------------------------------------------------------

*In vitro* assays of nisin release from the liposomes were performed by the method of previous report \[[@R10]\]. Nisin-loaded liposome (100 pmol as the nisin equivalent) in 200 µl of 5 mM sodium citrate (pH 7.0) containing 0.01% Triton X-100 was incubated in 96-well microplates at 37°C. At the appropriate times, the supernatants obtained by centrifuging the liposomes at 10,000×*g* for 10 min were assayed fluorometrically using the CBQCA quantitation kit. The amounts of nisin are expressed as the cumulative percentages of nisin released at each time point.

Statistical Analysis
--------------------

Assays were performed in triplicate, and values are reported as the mean. The standard deviation was \< 5% for all assays. The statistical significance of differences between groups was assessed using the Student *t*-test, and *P* \< 0.05 was considered statistically significant.

RESULTS
=======

The encapsulation efficiencies of nisin to the FDEL were between 70%-80%, with the differences possibly due to the variation within the experiment. The first step of this study was to examine the effects of charge on liposome-encapsulated nisin as the efficiency for bactericidal activity against *S. mutans in vitro*. To assess the contribution of charge on vesicles, we examined the effect of the cationic lipid PS, the anionic lipid DPPG, and the electroneutral lipids DPPE and SPS at pH 7.0. The results of the MIC assay, presented in Fig. (**[1](#F1){ref-type="fig"}**) indicated that the cationic liposome, nisin-loaded DPPC/PS, showed 2 fold higher bactericidal activity against *S. mutans* than DPPC-encapsulated nisin as the control liposome (*P* \< 0.05), and the liposome achieved most effective bactericidal activity (75 pmol as the nisin equivalent). The control liposome nisin-loaded DPPC exhibited slightly higher MIC value (150 pmol as the nisin equivalent) than that of naked nisin (175 pmol) in our assay conditions. The neutral liposomes nisin-loaded DPPC/DPPE and DPPC/SPS showed 1.3 and 1.7 fold higher MIC values, respectively (112 and 87.5 pmol as the nisin equivalent, respectively) than the control liposome. In contrast, the anionic liposome nisin-loaded DPPC/DPPG showed the lowest bactericidal effect (250 pmol as the nisin equivalent) in liposomes, and the effect was lower (0.6 fold) than that of the control liposome. Thus, the nisin-loaded liposome vesicles with positively charged lipids PS apparently increased the bactericidal activity.

The next step of this study was to examine the inhibition of insoluble glucan synthesis by liposome preparations with the above lipid compositions. The findings shown in Fig. (**[2](#F2){ref-type="fig"}**) indicated the marked inhibition of insoluble glucan synthesis by the cationic liposome nisin-loaded DPPC/PS with 3.4 fold higher inhibition than that of DPPC-encapsulated nisin as the control at the endpoint of incubation (3.75 h; *P* \< 0.05). DPPC-encapsulated nisin at 75 pmol as the nisin equivalent exhibited higher inhibition (1.4 fold) to insoluble glucan synthesis compared with the effect of naked nisin. The neutral liposomes nisin-loaded DPPC/DPPE and DPPC/SPS achieved significantly higher inhibition of glucan synthesis than that of DPPC-encapsulated nisin (1.4 and 1.7 fold, respectively). In contrast, the anionic liposomes nisin-loaded DPPC/DPPG achieved an inhibition equivalent to that of naked nisin, and the inhibiting profile was lower than that of the buffer alone (0.67 fold). The anionic liposome-encapsulated nisin demonstrated the lowest inhibitory effect of insoluble glucan synthesis (at 3.75 h). Inhibition of the glucan synthesis by these charged liposome-encapsulated nisin was essentially equivalent up to 1.5 h incubation, and the composition of nisin-loaded DPPC/PS was apparently increasing the inhibition after 2.25 h incubation. To evaluate the potential significance of bactericidal activity and inhibitory effect of charged vesicles on glucan synthesis, we examined the *in vitro* release assay of these encapsulated nisin (Fig. **[3](#F3){ref-type="fig"}**). The cationic liposome nisin-loaded DPPC/PS achieved 41% of releasing capacity based upon the 2 h incubation. At the same time point, DPPC-encapsulated nisin as the control liposome released 80% of nisin (*P* \< 0.05). The anionic liposome nisin-loaded DPPC/DPPG released nisin at similar levels of DPPC-encapsulated nisin as the control. Thus, the *in vitro* release assay of the liposome formulations showed that the extent of cationic vesicle is significant.

DISCUSSION
==========

We are taking steps toward optimizing liposome-based nisin to improve the efficiency of bactericidal activity against cariogenic streptococci for the purpose of prevention of dental caries \[[@R10]\]. Our recent study indicated that the acyl chain length of lipids in liposome affects the retaining of encapsulated nisin and suggests that the hydrophobicity of vesicle is a factor necessary for the sustainable bactericidal activity of nisin \[[@R11]\]. Furthermore, we focused the investigation regarding the effects of charge of composed lipids on liposome-encapsulated nisin for the bactericidal activity against *S. mutans,* and inhibition of insoluble glucan synthesis by the streptococci for the purpose of optimizing the sustained effect of the encapsulated nisin. For example, there are reports that the charge on vesicles affects the effective induction of bactericidal activity of the liposome-encapsulated antibiotics \[[@R16]\]. Some reports have determined that positively charged liposomes evoke more effective bioactivity of encapsulated molecules than nonionic vesicles \[[@R17], [@R18]\]. These reports determined that charged lipids interact with the target molecules. We observed that nisin-loaded DPPC/PS as the cationic liposome was more effective in terms of bactericidal activity than electroneutral or anionic liposome-encapsulated nisin at pH 7.0 in our experimental conditions. A related report has shown that the level of release of encapsulated peptides at the preferred ratios from cationic liposomes was sustained in comparison with that of neutral or anionic liposomes \[[@R19]\]. Furthermore, it is possible that cationic lipids such as PS interact with membrane of streptococci, but anionic or neutral lipids do not associate with the membrane. In this study, combinations of naked nisin plus appropriate empty liposomes or empty liposomes alone served as the control for individual liposome preparations. However, the combination of empty cationic liposome plus naked nisin or empty cationic liposome alone did not affect the evoked bactericidal activity against *S. mutans* as compared with cationic liposome-encapsulated nisin. Because cationic liposomes are effective carriers for several molecules, properties of the vesicles indicate that the vesicles not only maintain the encapsulated nisin at a stable state but also exert bactericidal activity against *S. mutans* by sustained releasing the nisin \[[@R17]\]. In addition, cationic liposomes show low toxicity to human cells and may have biomedical applications \[[@R19]\]. Thus, we expect to exploit cationic liposome-encapsulated nisin as the prophylactics to dental caries. Chemical features of liposome vesicles are being investigated to determine their use for encapsulating the bioactive molecule nisin *in vitro*. Additional efforts aimed at optimizing the vesicle formulation are expected, and our continuing studies should improve the oral health.

CONCLUSION
==========

In this study, the cationic liposome nisin-loaded DPPC/PS could exert a sustained bactericidal effect against *S. mutans* and its inhibition of insoluble glucan synthesis *in vitro*. Optimizing the ability of cationic liposome-encapsulated nisin may improve oral health.
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![Bactericidal activity of liposome-encapsulated nisin against *Streptococcus mutans*. Exponentially proliferating cultures of *S*. *mutans* 10449 (turbidity of 0.02 at 600 nm) were incubated for 4 h at 37°C in 0.2 ml of Todd Hewitt Broth in the presence of nisin-loaded liposome, an equivalent concentration of naked nisin, or buffer. A minimum inhibitory concentration (MIC) assay as indicative of the bactericidal activity of individual samples was quantified using resazurin dye. Symbols indicate the lipid formulations of liposomes and controls. \**P* \< 0.05 indicates a significant difference of MIC values of the reaction mixtures containing DPPC/PS-encapsulated nisin compared with those of the control liposome, nisin-loaded DPPC. Values represent the mean of triplicate replications and the bars represent the standard deviation of sample means.](TODENTJ-10-360_F1){#F1}

![Effect of liposome-encapsulated nisin on insoluble glucan synthesis by *Streptococcus mutans*. Exponentially proliferating cultures of *S. mutans* 10449 (turbidity of 0.02 at 600 nm) were incubated in Todd Hewitt Broth containing 0.25% sucrose at 37°C for 3.75 h in the presence of liposome-encapsulated nisin at concentrations equivalent to that of naked nisin, or naked nisin alone. Symbols indicate the lipid formulations of liposomes and controls. \* *P* \< 0.05 compared with the control liposome nisin-loaded DPPC. Values represent the mean of triplicate replications and the bars represent the standard deviation of sample means.](TODENTJ-10-360_F2){#F2}

![*In vitro* nisin release assay from liposome-encapsulated nisin. Liposome-encapsulated nisin was incubated in 10 mM sodium citrate (pH 7.0) containing 0.01% Triton X-100 at 37°C. At the appropriate incubation periods, amounts of nisin released into the supernatant at 10,000×*g* for 10 min were quantitated. The levels of nisin are expressed as the cumulative percentage release. The maximum value was defined as 100% release. Symbols indicate the lipid formulations of liposomes. The assays were performed in triplicates at each time point, and the bars represent the standard deviation of sample means. \* *P* \< 0.05 compared with the group of DPPC-encapsulated nisin.](TODENTJ-10-360_F3){#F3}
